Antengene (DB:722) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

722 Overzicht aandelen

Antengene Corporation Limited, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling van nieuwe oncologische therapieën in Groot-China en internationaal.

Over het bedrijf

722 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 66.1% per jaar groeien

De winst is de afgelopen 5 jaar met 23% per jaar gegroeid

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( €526M )

Antengene Corporation Limited Concurrenten

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€61.9m

MPH Health Care

DB:93M1

€101.0m

Pierrel

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Antengene
Historische aandelenkoersen
Huidige aandelenkoers	HK$0.062
52 Week Hoogtepunt	HK$0.24
52 Week Laag	HK$0.025
Bèta	0.86
11 maand verandering	40.91%
3 maanden verandering	6.90%
1 Jaar Verandering	-47.90%
33 jaar verandering	-94.56%
5 jaar verandering	n/a
Verandering sinds IPO	-96.52%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	722	DE Pharmaceuticals	DE Markt
7D	63.2%	-0.8%	-1.0%
1Y	-47.9%	-11.6%	12.8%

Rendement versus industrie: 722 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -11.5 % opleverde.

Rendement versus markt: 722 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 13.3 % opleverde.

Prijsvolatiliteit

Is 722's price volatile compared to industry and market?
722 volatility
722 Average Weekly Movement	39.1%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 722 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 722 is het afgelopen jaar gestegen van 22% naar 39%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	178	Jay Mei	www.antengene.com

Antengene Corporation Limited, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling van nieuwe oncologische therapieën in Groot-China en internationaal. De gecommercialiseerde activa van het bedrijf omvatten ATG-010 (selinexor), een orale SINE-verbinding voor de behandeling van verschillende hematologische maligniteiten en vaste tumoren, waaronder recidief/refractair multipel myeloom (rrMM), recidief/refractair diffuus groot B-cel lymfoom en multipel myeloom (MM) bij volwassen patiënten op het Chinese vasteland, in Singapore, Australië, Hong Kong, Macau en Taiwan. Haar productkandidaten in een laat stadium omvatten ATG-008 (onatasertib), een mTOR-kinaseremmer voor de behandeling van baarmoederhalskanker en andere vergevorderde vaste tumoren.

Antengene Corporation Limited Samenvatting

Hoe verhouden de winst en inkomsten van Antengene zich tot de beurswaarde?
722 fundamentele statistieken
Marktkapitalisatie	€63.05m
Inkomsten(TTM)	-€68.42m
Inkomsten(TTM)	€7.24m

8.7x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is 722 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
722 resultatenrekening (TTM)
Inkomsten	CN¥56.07m
Kosten van inkomsten	CN¥8.50m
Brutowinst	CN¥47.57m
Overige uitgaven	CN¥577.09m
Inkomsten	-CN¥529.52m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.78
Brutomarge	84.84%
Nettowinstmarge	-944.43%
Schuld/Eigen Vermogen Verhouding	18.1%

Hoe presteerde 722 op de lange termijn?

Bekijk historische prestaties en vergelijking

722 Overzicht aandelen

Beloningen

Risicoanalyse

Antengene Corporation Limited Concurrenten

DB:0RX

€65.0m

XTRA:HIGH

€61.9m

DB:93M1

€101.0m

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Recent updates

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Full year 2023 earnings released: CN¥0.94 loss per share (vs CN¥0.97 loss in FY 2022)

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Market cap size

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Less than half of directors are independent

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Less than half of directors are independent

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Rendement voor aandeelhouders

Prijsvolatiliteit